Literature DB >> 19039643

Cervical metastases of glucagonoma in a patient with multiple endocrine neoplasia type 1: report of a case.

Jean M Butte1, Pablo H Montero, Antonieta Solar, Javiera Torres, Pablo R Olmos, Ignacio Goñi, Juan C Quintana, Jorge Martínez, Osvaldo Llanos.   

Abstract

Multiple endocrine neoplasia type 1 (MEN 1) is a syndrome characterized by tumors of the parathyroid glands, pancreatic islet cells, duodenum, and pituitary gland. We report a case of cervical metastases of glucagonoma with MEN 1. The patient was a 34-year-old woman admitted to our hospital with epigastric pain. Her medical history included two resections of prolactinoma and two upper GI hemorrhages secondary to duodenal ulcers. Computed tomography (CT) showed two hypervascular lesions in the tail of the pancreas and cervical ultrasound showed multiple hypoechogenic ovoid images in the neck. A cervical CT scan confirmed two 15-mm lymph nodes in the left cervical region and 111In-DOTATOC imaging showed focal abnormal somatostatin expression in the pancreatic tail and the cervical nodes. The patient had asymptomatic hypoglycemic episodes, with blood sugar levels as low as 30 mg/dl, which raised our suspicion of MEN 1 associated with pancreatic insulinoma. Thus, we performed a distal pancreatectomy with bilateral cervical dissection and parathyroid gland resection. Histopathological examination revealed 12 pancreatic tumors as well as metastases in four cervical lymph nodes. The resected parathyroid glands had normal structure, suggesting parathyroid hyperplasia. A follow-up CT scan, 18 months after surgery, showed new tumors in the head of the pancreas and in the duodenal wall. A pancreatoduodenectomy was performed and histopathological examination revealed nine nonfunctioning endocrine tumors in the pancreas, one tumor in the duodenal wall, and metastases in two peripancreatic lymph nodes. The patient recovered well and remains asymptomatic.

Entities:  

Mesh:

Year:  2008        PMID: 19039643     DOI: 10.1007/s00595-008-3763-1

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  19 in total

Review 1.  Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara Grana; Paola Rocca; Mirco Bartolomei; Marco Chinol; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-19       Impact factor: 9.236

2.  Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience.

Authors:  Paulus G Schurr; Tim Strate; Kim Rese; Jussuf T Kaifi; Uta Reichelt; Susanne Petri; Helge Kleinhans; Emre F Yekebas; Jakob R Izbicki
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

3.  Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1.

Authors:  Detlef K Bartsch; Volker Fendrich; Peter Langer; Ilhan Celik; Peter H Kann; Matthias Rothmund
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

4.  Malignant nonfunctioning endocrine tumors of the pancreas: predictive factors for survival after surgical treatment.

Authors:  Jun Chul Chung; Dong Wook Choi; Sung Ho Jo; Jin Seok Heo; Seong Ho Choi; Yong Il Kim
Journal:  World J Surg       Date:  2007-03       Impact factor: 3.352

5.  Multiple endocrine neoplasia type 1 (MEN 1) is associated with an increased prevalence of diabetes mellitus and impaired fasting glucose.

Authors:  Roland W McCallum; Venkat Parameswaran; John R Burgess
Journal:  Clin Endocrinol (Oxf)       Date:  2006-08       Impact factor: 3.478

6.  Aggressive surgery for metastatic liver neuroendocrine tumors.

Authors:  Jeffrey A Norton; Robert S Warren; Mary G Kelly; Marlene B Zuraek; Robert T Jensen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

Review 7.  Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases.

Authors:  J Soga; Y Yakuwa
Journal:  J Hepatobiliary Pancreat Surg       Date:  1998

8.  An immunohistochemical study of glucagonoma conducted on the metastatic lymph nodes from a patient with recurrent metastatic glucagonoma: report of a case.

Authors:  N Kawakita; Y Nagahata; K Yoshizumi; T Wada; M Yamamoto; Y Saitoh; T Urakawa
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

Review 9.  Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.

Authors:  W W de Herder; L J Hofland; A J van der Lely; S W J Lamberts
Journal:  Endocr Relat Cancer       Date:  2003-12       Impact factor: 5.678

10.  Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

Authors:  D J Kwekkeboom; W H Bakker; B L Kam; J J M Teunissen; P P M Kooij; W W de Herder; R A Feelders; C H J van Eijck; M de Jong; A Srinivasan; J L Erion; E P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-09       Impact factor: 9.236

View more
  2 in total

Review 1.  Phenotypes Associated With MEN1 Syndrome: A Focus on Genotype-Phenotype Correlations.

Authors:  Chiara Mele; Monica Mencarelli; Marina Caputo; Stefania Mai; Loredana Pagano; Gianluca Aimaretti; Massimo Scacchi; Alberto Falchetti; Paolo Marzullo
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-18       Impact factor: 5.555

2.  Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Marc J Berna; Robert T Jensen
Journal:  Medicine (Baltimore)       Date:  2013-05       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.